PARI Pharma's Altera Delivers Gilead Sciences, Inc.'s Cayston, Approved by European Commission to Treat Cystic Fibrosis

Published: Sep 24, 2009

MONTEREY, Calif., Sept. 23 /PRNewswire/ -- PARI Pharma's Altera, which uses eFlow Technology, is the first drug-specific nebuliser for cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston. Cayston, aztreonam lysine 75 mg powder and solvent for nebuliser solution, is a new antibiotic that received conditional marketing approval from the European Commission as a suppressive therapy for cystic fibrosis patients, 18 years and older, who have chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) infection.

Back to news